Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Breakthrough Therapy Designation

- PMLiVE

EMA backs drugs from Novo, Otsuka, AZ, Janssen, GSK

Nine new branded medicines recommended for use in Europe

- PMLiVE

Boehringer to work with Roche on cancer diagnostics

Will collaborate with Roche subsidiary Ventana Medical Systems

- PMLiVE

FDA to review AZ’s fish oil drug Epanova

Hypertriglyceridaemia treatment acquired as part of Omthera takeover

- PMLiVE

Dendreon’s cancer vaccine wins EU approval

Provenge approved for use in prostate cancer three years after US recommendation

- PMLiVE

Eisai expands in Europe with new Belgium business

Will coordinate local reimbursement for cancer drug Halaven

- PMLiVE

Personalised understanding: oncology and orphan diseases

Improvements in our understanding of cancer are drawing the orphan drug and oncology worlds ever closer together

Bristol-Myers Squibb (BMS) building

BMS’ Yervoy fails prostate cancer trial

Unable to improve overall survival in phase III

- PMLiVE

FDA panel backs Perjeta in early breast cancer

Unanimous recommendation for use alongside Herceptin

- PMLiVE

AZ licenses Merck ovarian cancer drug

Pays $50m upfront for MK-1775

- PMLiVE

AZ sponsors heart attack risk app

GRACE 2.0 app aims to help HCPs decide on the most appropriate treatments

- PMLiVE

Celgene wins US pancreatic cancer indication for Abraxane

Adds to breast cancer and lung cancer indications

- PMLiVE

Rigel plans job cuts in R&D restructure

Follows failure of fostamatinib disodium in rheumatoid arthritis trial

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links